Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Multiple Sclerosis (MS)

In brief

This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).

Key facts

Study ID

NCT04203498

Run by

Jazz Pharmaceuticals

People needed

139

Starts

2020-10-01

Expected to finish

2023-02-28

Last updated by the study team

2024-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Criteria at screening:
• Participant is male or female aged 18 years or above.
• Participant has had a diagnosis with any disease subtype of multiple sclerosis (MS), by revised 2017 McDonald criteria, for at least 12 months prior to screening and is expected to remain stable for the duration of the trial.
• Participant has had treatment with at least 1 optimized oral antispasticity therapy prior to Visit 1 that must include either oral baclofen or oral tizanidine (monotherapy or combination therapy).
• Participant is currently receiving optimized treatment with at least 1 oral antispasticity medication (baclofen, tizanidine, and/or dantrolene) and has been stable for at least 30 days prior to screening.
• If the participant is currently receiving an approved MS disease-modifying therapy, it must be at a stable dose for at least 3 months prior to screening and is expected to remain stable for the duration of the trial.

You may not qualify if…

• Participant has any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity.
• Participant has had a relapse of MS within the 60 days prior to screening (Visit 1).
• Participant is currently using or has used cannabis or a cannabinoid-derived product for medicinal or recreational use (within 30 days of screening) and is unwilling to abstain for the duration of the trial.
• Participant is currently using botulinum toxin injection for the relief of spasticity (within 6 months of screening) and is unwilling to abstain for the duration of the trial.
• Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP.
• Participant is male and fertile unless willing to ensure that he uses male contraception or remains sexually abstinent during the trial and for 3 months thereafter.
• Participant is female and of childbearing potential unless willing to ensure that she uses a highly effective method of birth control during the trial and for 3 months thereafter.
• Participant is female and pregnant, lactating, or planning pregnancy during the course of the trial or within 3 months thereafter.
• Participant has received an IMP within the 30 days prior to screening.
• Participant has a history of severe psychiatric disorder that may be exacerbated by the use of a cannabinoid-containing product.
• Participant has any known or suspected history of alcohol or substance abuse (including opiate abuse) or dependence within 1 year prior to screening.
• Participant is currently taking drugs that are solely metabolized by UGT1A9 and UGT2B7.
• Participant is currently taking strong currently taking strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort).

Where it is running

• University of Alabama at Birmingham School of Medicine — Birmingham, Alabama, United States
• Neurostudies - Port Charlotte — Port Charlotte, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Accel Research Sites - Enterprise — Tampa, Florida, United States
• Shepherd Center — Atlanta, Georgia, United States
• Consultants in Neurology - Northbrook — Northbrook, Illinois, United States
• American Health Network of Indiana — Avon, Indiana, United States
• Ochsner Medical Center — New Orleans, Louisiana, United States
• The Multiple Sclerosis Center For Innovations In Care — St Louis, Missouri, United States
• Raleigh Neurology Associates - Raleigh Location — Raleigh, North Carolina, United States
• University of Cincinnati (UC) Health — Dayton, Ohio, United States
• Neurology Clinic - Cordova — Cordova, Tennessee, United States
• Hope Neurology — Knoxville, Tennessee, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• Central Texas Neurology Consultants — Round Rock, Texas, United States
• Poliklinika Choceň — Choceň, Pardubice, Czechia
• Neurologie Taláb Radomír Doc. MUDr., CSc — Hradec Králové, Czechia
• Nemocnice Jihlava — Jihlava, Czechia
• Fakultní Nemocnice Královské Vinohrady — Prague, Czechia
• Krajská Zdravotní - Nemocnice Teplice — Teplice, Czechia
• Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD — Poznan, Greater Poland Voivodeship, Poland
• Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych — Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
• Wromedica Centrum Zdrowia — Wroclaw, Lower Silesian Voivodeship, Poland
• Centrum Medyczne Neuroprotect — Warsaw, Masovian Voivodeship, Poland
• Centrum Medyczne Pratia - Warszawa — Warsaw, Masovian Voivodeship, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.